{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:00:37Z","timestamp":1773381637901,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.cjca.2022.04.005","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:12:37Z","timestamp":1649934757000},"page":"1378-1383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Loperamide Cardiac Toxicity: Pathophysiology, Presentation, and Management"],"prefix":"10.1016","volume":"38","author":[{"given":"Peter E.","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David N.","family":"Juurlink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2022.04.005_bib1","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/0006-2952(79)90450-7","article-title":"Distribution of loperamide in the intestinal wall","volume":"28","author":"van Nueten","year":"1979","journal-title":"Biochem Pharamcol"},{"key":"10.1016\/j.cjca.2022.04.005_bib2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/164_2016_116","article-title":"Insights into the role of opioid receptors in the GI tract: experimental evidence and therapeutic relevance","volume":"239","author":"Galligan","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.cjca.2022.04.005_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/003655201300191996","article-title":"Antisecretory effect of loperamide in colon epithelial cells by inhibition of basolateral K+ conductance","volume":"36","author":"Epple","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cjca.2022.04.005_bib4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0022-3565(25)21735-9","article-title":"Loperamide: blockade of calcium channels as a mechanism for antidiarrheal effects","volume":"231","author":"Reynolds","year":"1984","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cjca.2022.04.005_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/j.1552-4604.1979.tb01654.x","article-title":"Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride","volume":"19","author":"Killinger","year":"1979","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cjca.2022.04.005_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003495-197815010-00003","article-title":"Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea","volume":"15","author":"Heel","year":"1978","journal-title":"Drugs"},{"key":"10.1016\/j.cjca.2022.04.005_bib7","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/clpt.1980.239","article-title":"Abuse potential of loperamide","volume":"28","author":"Jaffe","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2022.04.005_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/clpt.1980.93","article-title":"Dependence liability of two antidiarrheals, nufenoxole and loperamide","volume":"27","author":"Korey","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2022.04.005_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/15563650.2018.1510128","article-title":"Loperamide misuse to avoid opioid withdrawal and to achieve a euphoric effect: high doses and high risk","volume":"57","author":"Lee","year":"2019","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.cjca.2022.04.005_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.drugalcdep.2012.11.003","article-title":"\u201cI just wanted to tell you that loperamide will work\u201d: a web-based study of extra-medical use of loperamide","volume":"130","author":"Daniulaityte","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.cjca.2022.04.005_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jemermed.2017.03.018","article-title":"Intentional misuse and abuse of loperamide: a new look at a drug with \u201clow abuse potential\u201d","volume":"53","author":"Borron","year":"2017","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.cjca.2022.04.005_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/15563650.2019.1681443","article-title":"Loperamide toxicity: recommendations for patient monitoring and management","volume":"58","author":"Eggleston","year":"2020","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.cjca.2022.04.005_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1211\/jpp.62.04.0001","article-title":"Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance","volume":"62","author":"Vandenbossche","year":"2010","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.cjca.2022.04.005_bib14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00228-004-0815-3","article-title":"Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes","volume":"60","author":"Kim","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2022.04.005_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1067\/mcp.2000.109156","article-title":"Increased drug delivery to the brain by P-glycoprotein inhibition","volume":"68","author":"Sadeque","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2022.04.005_bib16","first-page":"405","article-title":"Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement","volume":"70","author":"Tayrouz","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2022.04.005_bib17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00228-006-0133-z","article-title":"Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide","volume":"62","author":"Niemi","year":"2006","journal-title":"Eur J Clin Pharamcol"},{"key":"10.1016\/j.cjca.2022.04.005_bib20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1124\/jpet.102.034728","article-title":"Piperine a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4","volume":"302","author":"Bhardwaj","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cjca.2022.04.005_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000343243","article-title":"Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects","volume":"91","author":"Bauer","year":"2013","journal-title":"Pharmacology"},{"key":"10.1016\/j.cjca.2022.04.005_bib22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00210-016-1286-7","article-title":"Proarrythmic mechanisms of the common antidiarrheal medication loperamide: revelations from the opioid abuse epidemic","volume":"389","author":"Kang","year":"2016","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.cjca.2022.04.005_bib23","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jacep.2016.07.008","article-title":"Potent inhibition of hERG channels by the over-the-counter antidiarrheal agent loperamide","volume":"2","author":"Klein","year":"2016","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cjca.2022.04.005_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jpba.2004.06.020","article-title":"LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsules in human volunteers","volume":"36","author":"Yu","year":"2004","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.cjca.2022.04.005_bib25","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jacep.2016.10.009","article-title":"An emerging malignant arrhythmia epidemic due to loperamide abuse: underlying mechanisms and clinical relevance","volume":"2","author":"Nattel","year":"2016","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cjca.2022.04.005_bib26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/15563650.2016.1159310","article-title":"Not your regular high: cardiac dysrhythmias caused by loperamide","volume":"54","author":"Wightman","year":"2016","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.cjca.2022.04.005_bib27","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1161\/CIRCULATIONAHA.118.037346","article-title":"Syncope with unusual wide complex arrhythmia in a young woman","volume":"183","author":"Minhas","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.04.005_bib28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jat\/bkw069","article-title":"Loperamide-related deaths in North Carolina","volume":"40","author":"Bishop-Freeman","year":"2016","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.cjca.2022.04.005_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.annemergmed.2017.04.008","article-title":"Clinical review: loperamide toxicity","volume":"70","author":"Wu","year":"2017","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.cjca.2022.04.005_bib30","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jemermed.2021.04.016","article-title":"A\u00a0case report of torsade de pointes and Brugada pattern associated with loperamide misuse and supratherapeutic loperamide concentrations","volume":"61","author":"Simon","year":"2021","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.cjca.2022.04.005_bib31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jelectrocard.2017.01.011","article-title":"Torsades de pointes with high-dose loperamide","volume":"50","author":"Kozak","year":"2017","journal-title":"J\u00a0Electrocardiol"},{"key":"10.1016\/j.cjca.2022.04.005_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/CIRCULATIONAHA.120.050587","article-title":"Cardiovascular toxicities associated with loperamide: analysis of the World Health Organization pharmacovigilance database","volume":"143","author":"Ollitrault","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.04.005_bib33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/15563650.2015.1026971","article-title":"Loperamide toxicokinetics: serum concentrations in the overdose setting","volume":"53","author":"Eggleston","year":"2015","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.cjca.2022.04.005_bib34","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/bcp.12793","article-title":"Activated charcoal for acute overdose: a reappraisal","volume":"82","author":"Juurlink","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2022.04.005_bib35","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.hrcr.2018.08.013","article-title":"Isoproterenol suppresses recurrent torsades de pointes in a patient with long QT syndrome type 2","volume":"4","author":"Suarez","year":"2018","journal-title":"HeartRhythm Case Rep"},{"key":"10.1016\/j.cjca.2022.04.005_bib36","unstructured":"DrugBank. Loperamide. Available at: https:\/\/go.drugbank.com\/drugs\/DB00836. Accessed January 23,\u00a02022."},{"key":"10.1016\/j.cjca.2022.04.005_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/15563659709001159","article-title":"Surveillance of loperamide ingestions: an analysis of 216 poison center reports","volume":"35","author":"Litovitz","year":"1997","journal-title":"J\u00a0Toxicol Clin Toxicol"},{"key":"10.1016\/j.cjca.2022.04.005_bib38","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1080\/15563650.2019.1580370","article-title":"Loperamide induced cardiac arrhythmia successfully supported with veno-arterial ECMO (VA-ECMO), molecular adsorbent recirculating system (MARS) and continuous renal replacement therapy (CRRT)","volume":"57","author":"Parker","year":"2019","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.cjca.2022.04.005_bib39","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.amjmed.2015.05.019","article-title":"The long QT teaser: loperamide abuse","volume":"128","author":"Enakpene","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2022.04.005_bib40","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/jce.13052","article-title":"Electrocardiographic abnormalities, malignant ventricular arrhythmias and cardiomyopathy associated with loperamide abuse","volume":"27","author":"Vaughn","year":"2016","journal-title":"J\u00a0Cardiovasc Electrophysiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X22002215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X22002215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:48:59Z","timestamp":1760107739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X22002215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0828282X22002215"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2022.04.005","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loperamide Cardiac Toxicity: Pathophysiology, Presentation, and Management","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2022.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}